Board of Directors

Overview

Members of our Board of Directors are appointed for a maximum term of four years - reappointment of Directors is done on a rotation basis.

 

The Board of Directors defines the strategic business guidelines and directions of the Company, and supervises their implementation. Subject to the powers expressly attributed to the Shareholders’ General Meeting, and within the scope of the company’s corporate purpose, the Board of Directors’ powers cover all issues relating to the proper management of the company and through its decisions the Board determines all matters falling within its authority.

Composition of the Board of Directors

The Board of Directors, appointed by the shareholders, is composed of 16 members, two of whom are employee representatives.

Frédéric Oudéa

Chairman of the Board of Directors

Term expires 2027

Paul Hudson

Chief Executive Officer

Term expires 2026

Christophe Babule

Director

Term expires 2026

Rachel Duan

Independent director

Term expires 2024

Carole Ferrand

Independent director

Term expires 2025

Lise Kingo

Independent director

Term expires 2024

Patrick Kron

Independent director

Term expires 2026

Wolfgang Laux

Employee of Sanofi, API Portfolio Leader (New Products and Launches) at Gentilly - Campus Val de Bièvre

Term expires 2025

Barbara Lavernos

Director

Term expires 2025

Fabienne Lecorvaisier

Independent director

Term expires 2025

Gilles Schnepp

Independent director

Term expires 2026

Diane Souza

Independent director

Term expires 2024

Thomas Südhof

Independent director

Term expires 2024

Ceng-Yann Tran

Director representing employees

Term expires 2025

Emile Voest

Independent director

Term expires 2025

Antoine Yver

Independent director

Term expires 2025

Board Diversity

Each year, the Board of Directors conducts a review to ensure that there is an appropriate balance in its composition. In particular, the Board seeks to ensure gender balance and a broad diversity of backgrounds and countries of origin, international experience, reflecting Sanofi’s status as a diversified global business.

 

Women represent 43% of members. 7 Directors are non-French. Above all, the Board seeks directors who show independence of mind and who are competent, dedicated and committed.

Independence of Board Members

Under the terms of the AFEP-MEDEF corporate governance code of listed corporations, a Director is independent when he or she has no relation of any kind whatsoever with the company, its group or its management that may interfere with his or her freedom of judgement.

 

79% of members are independent (according to French Law, Directors representing employees are excluded when calculating the proportion of independent Directors).

Summary table

DirectorAgeNationalityFirst AppointedTerm expiresSeniorityACAGCCCSCSciC

Frédéric Oudéa

Chairman of the Board of Directors
59FrenchMay 2023General Meeting 2027<1XCX

Paul Hudson

Chief Executive Officer
55BritishSeptember 2019General Meeting 20263X

Christophe Babule

Director
57FrenchFebruary 2019General Meeting 20264X

Rachel Duan

Independent director
52ChineseApril 2020General Meeting 20243X

Carole Ferrand

Independent director
53FrenchMay 2022General Meeting 20251X

Lise Kingo

Independent director
61DanishApril 2020General Meeting 20243X

Patrick Kron

Independent director
69FrenchMay 2014General Meeting 20269XCX

Wolfgang Laux

Employee of Sanofi, API Portfolio Leader (New Products and Launches) at Gentilly - Campus Val de Bièvre
55GermanApril 2021General Meeting 20252X

Barbara Lavernos

Director
55French and GermanApril 2021General Meeting 20252XX

Fabienne Lecorvaisier

Independent director
60FrenchMay 2013General Meeting 202510C

Gilles Schnepp

Independent director
64FrenchMay 2020General Meeting 20263CX

Diane Souza

Independent director
70AmericanMay 2016General Meeting 20247XX

Thomas Südhof

Independent director
67German and AmericanJanuary 2016General Meeting 20247C

Ceng-Yann Tran

Director representing employees
57FrenchMay 2021General Meeting 20252

Emile Voest

Independent director
63DutchMay 2022General Meeting 20251X

Antoine Yver

Independent director
65French, American, SwissMay 2022General Meeting 20251X

AC: Audit Committee
AGC: Appointments and Governance Committee
CC: Compensation Committee
SC: Strategy Committee
SciC: Scientific Committee
C: Chairman/Chairwoman